Genentech, Inc.
NEWS
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
In an initial public offering, Unum Therapeutics snagged nearly $70 million to fund its antibody-coupled T-cell receptor technology.
The Hemophilia Federation of America and the National Hemophilia Foundation announced that they had been contacted by Genentech, a Roche company, about the deaths of five patients receiving Hemlibra (emicizumab-kxwh) for hemophilia A.
Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
Tecentriq’s Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.
John Reed, who for five years has led Roche’s Pharma Research and Early Development (pRED) research group, is stepping down for personal reasons.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections.
JOBS
IN THE PRESS